Pharmaceutical company that co-developed cancer drug Opdivo, earning royalties alongside its own drug pipeline.
Pharmaceutical company that co-developed cancer drug Opdivo, earning royalties alongside its own drug pipeline.
Sells Opdivo itself in Japan, South Korea and Taiwan and collects royalties on sales elsewhere, where Bristol Myers Squibb markets it. A patent settlement also brings royalties on Merck's rival drug Keytruda. Buying US drugmaker Deciphera in 2024 added cancer drugs that Ono now sells directly in the US.
In one line: A specialty pharma with a blockbuster oncology royalty stream.
Moat: narrow (IP / patents). Patent-protected Opdivo royalty stream and pipeline in a high-value oncology franchise.
Headquarters: Osaka, Japan · Founded: 1717 · Employees: 4,206
Size ONO Pharmaceutical (4528.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $7.33B, the 181st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,489 on 18 Nov 2026.
Performance Over six months the shares fell 1.8%, against +5.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue fell 2.5% over the last twelve months (peer median +12.5%); the operating margin is 22.1% (peer median 13.7%).
Valuation It trades at 15.3× forward earnings against a peer median of 19.3× (7th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.3 points above its cost of capital (5.9% WACC).
Next results Next results expected around 1 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥491B | ¥516B | ¥487B | ¥503B | ¥447B |
| Revenue growth | — | +6% | -3% | +12% | — |
| Gross profit | ¥364B | ¥371B | ¥335B | ¥373B | ¥334B |
| EBITDA | ¥146B | ¥141B | ¥90.3B | ¥182B | ¥170B |
| Net income | ¥74.6B | ¥69.8B | ¥50.0B | ¥128B | ¥113B |
| Free cash flow | ¥127B | ¥131B | ¥77.0B | ¥107B | ¥154B |
| Capital expenditure | ¥11.8B | ¥53.3B | ¥7.99B | ¥20.8B | ¥14.5B |
| Total debt | ¥110B | ¥121B | ¥147B | ¥8.86B | ¥9.17B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ONO Pharmaceutical 4528.T | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 9.2× | -13.1% |
| Chugai Pharmaceutical 4519.T | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4528.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | +2.2% | 11th highest of 21 |
| 6-month return | -1.8% | +5.9% | 8th lowest of 20 |
| Distance from 52-week high | -6.9% | -12.9% | 7th highest of 21 |
| Revenue growth (TTM) | -2.5% | +12.5% | lowest of 20 |
| Operating margin | 22.1% | 13.7% | 3rd highest of 20 |
| Forward P/E | 15.3× | 19.3× | 7th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -6.8% | 7.3% | 3rd least demanding of 14 |
| Growth delivered (Del g) | +10.8% | +8.7% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -17.6 pp | -3.7 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +4.3 pp | +1.6 pp | 8th highest of 19 |
| EV / EBITDA | 7.0× | 23.1× | cheapest of 11 |
| Net debt / EBITDA | -1.0× | 0.8× | 3rd least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |